Combined Therapy of COVID-19 Infection Consequences

Воробьева, О. В.; Moscow, Russian Federation

doi:10.31550/1727-2378-2021-20-5-13-19

2021

DOI: 10.31550/1727-2378-2021-20-5-13-19

|View full text |Cite

Combined Therapy of COVID-19 Infection Consequences

О. В. Воробьева¹,

Russian Federation Moscow²

Abstract: Objective of the Review: To present clinical characteristics, pathogenic mechanisms and therapies of Long COVID-19. Key Points. Long COVID-19 is a set of chronic symptoms, which can be recorded in patients after acute COVID-19. These conditions are characterised by various types and combinations of clinical symptoms during various periods of time. Usually, there are two groups of symptoms: pulmonary symptoms and a set of symptoms similar to chronic fatigue syndrome. Balanced combined therapies of Long COVID-19… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Cognitive impairment in COVID-19 patients complicated by depression after the acute phase

Vorob’еva,

Shindryaeva,

Fateeva

2024

Neurology bulletin

View full text Add to dashboard Cite

BACKGROUND: Damage of the central nervous system in COVID-19 patients includes cognitive impairment, depression, and fatigue. Clinical features of cognitive impairment after the acute phase of COVID-19 and the contribution of various factors to the development of memory deficit have not been fully studied. AIM: This study assesses the clinical features of cognitive impairment in COVID-19 patients complicated by depression after the acute phase and analyzes how health and demographic factors contribute to the development of cognitive impairment. MATERIALS AND METHODS: The observational cross-sectional study includes 33 patients aged 18–80 (mean age: 53.5; women: 60.6%) who meet the eligibility criteria. All subjects had a clinical semi-structured interview, a general clinical examination, MoCA, HDRS-17, and MFI-20 neuropsychological tests. RESULTS: The average MoCA-total score was 23.8±2.2. Cognitive impairments primarily affected memory (average MoCA memory score: 10.5±2.0), executive functions (average MoCA executive functioning score: 9.5±1.1), and attention (average MoCA attention score: 14.8±1.9). There is a strong negative correlation of HDRS-17 and MoCA-total values ( r=−0.72; p0.05), executive functioning index ( r=−0.82; p0.05), and memory index ( r=−0.85; p0.05). Age (β=−0.028; p=0.03), number of cardiovascular risk factors (β=−0.53; p=0.001), severity of COVID-19 in the acute phase (β=−0.97; p=0.001) and depression (β=−0.065; p=0.02) are the main contributors to cognitive impairment. CONCLUSION: Multi-domain cognitive impairment with predominant deterioration of executive functions, memory and attention was detected in patients who had COVID-19 complicated by depression after the acute phase. The key factors of, or main contributors to, cognitive impairment were identified, which can help select the best targeted therapy for this category of patients.

show abstract

Cognitive impairment in COVID-19 patients complicated by depression after the acute phase

Vorob’еva,

Shindryaeva,

Fateeva

2024

Neurology bulletin

View full text Add to dashboard Cite

show abstract

Hypertension and cognitive impairment: relationship and management approaches

2022

View full text Add to dashboard Cite

Hypertension (HTN) is currently regarded as the most prevalent risk factor, which can lead to both stroke and cognitive impairment. The versatility and similarity of HTN and chronic cerebral ischemia (CCI) pathogenetic mechanisms should be considered in prevention and treatment strategies. The severity of pathological changes in central nervous system (CNS) depends on the degree of HTN and concomitant neurological pathologies. The drug effects on both vascular and cognitive dysfunctions as well as comorbidities and polypharmacy should be considered. The use of agents with polymodal pleiotropic effects both at metabolic and circulation levels appears feasible and rewarding ethylmethylhydroxypyridine malate can be recommended in HTN co-existent with CCI and cognitive disorders. The combination therapy of ethylmethylhydroxypyridine malate with antihypertensive, anti-ischemic drugs, anticoagulants and statins has been proven to be safe, shows low risk of adverse events and can be implemented in a wide range of vascular and comorbid diseases.

show abstract

Clinical observation of the long-term course of COVID-19 infection in a patient with an immunodeficiency condition

Nikolaeva,

Voronkova,

Glukhova

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

The new coronavirus infection caused by the SARS-CoV-2 virus has become a real challenge for the world’s population. Despite the fact that vaccines have been developed and the effectiveness of antiviral drugs has been demonstrated, COVID-19 continues to be an urgent problem. SARS-CoV-2 is genetically modified due to the accumulation of mutations, new strains with high virulence appear that distort the immune response. In addition, it has been shown that the virus can persist in the body for a long time, which ensures the maintenance of an inflammatory response and causes the persistence and recurrence of symptoms after acute infection, especially in certain groups of patients. The article presents a clinical case of a long-term course of new coronavirus infection with predominant lung damage in the form of interstitial changes and persistent inflammation for 7 months from the moment of diagnosis against the background of an immunodeficiency condition due to the patient’s lymphoma in remission after polychemotherapy, exclusion of pulmonary embolism and progression of lymphoproliferative disease. The article highlights the difficulties of determining the criteria for a post-COVID and the features of its treatment using long-term therapy with systemic glucocorticosteroids, inhalation administration of tauractant (Surfactant-BL) in comparison with the dynamic assessment of total ventilation disorders and dynamic control of MSCT of the chest organs. Thus, the importance of identifying risk factors for the progression of COVID-19-associated conditions in patients with different comorbid backgrounds and identifying criteria for the development of new long-COVID treatment strategies is emphasized.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Combined Therapy of COVID-19 Infection Consequences

Cited by 3 publications

References 20 publications

Cognitive impairment in COVID-19 patients complicated by depression after the acute phase

Cognitive impairment in COVID-19 patients complicated by depression after the acute phase

Hypertension and cognitive impairment: relationship and management approaches

Clinical observation of the long-term course of COVID-19 infection in a patient with an immunodeficiency condition

Contact Info

Product

Resources

About